---
figid: PMC3463457__auto-8-1542-g1
figlink: /pmc/articles/PMC3463457/figure/F1/
number: F1
caption: Figure 1. The induction of autophagy in glioma cells treated with 2OHOA.
  The illustration on the left depicts the membrane structure and the active (black)
  or inactive (red) cell signals in glioma cells. High PE and low SM levels favor
  the activation of the MAPK pathway, which in turn induces the activity of the cyclin-CDK
  and PI3K pathways. The illustration on the right depicts the membrane lipid status
  in 2OHOA-treated cells, with more SM and less PE than untreated glioma cells, which
  causes the uncoupling of RAS and the concomitant inactivation of the MAPK and related
  pathways. Activation of FOXO1, overexpression of CDKN1B, hypophosphorylation of
  RB1 and inactivation of AKT1, contributes to the molecular scenario associated with
  the activation of autophagy in glioma but not normal cells. In this context, the
  membrane lipid structure appears to be the most upstream event that controls cell
  proliferation, differentiation and autophagy in glioma cells, SGMS thereby representing
  a new target for anticancer therapies.
pmcid: PMC3463457
papertitle: Normalization of sphingomyelin levels by 2-hydroxyoleic acid induces autophagic
  cell death of SF767 cancer cells.
reftext: Silvia Terés, et al. Autophagy. 2012 Oct 1;8(10):1542-1544.
pmc_ranked_result_index: '191834'
pathway_score: 0.9439197
filename: auto-8-1542-g1.jpg
figtitle: Normalization of sphingomyelin levels by 2-hydroxyoleic acid induces autophagic
  cell death of SF767 cancer cells
year: '2012'
organisms: Homo sapiens
ndex: ff2ebf7c-deb2-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3463457__auto-8-1542-g1.html
  '@type': Dataset
  description: Figure 1. The induction of autophagy in glioma cells treated with 2OHOA.
    The illustration on the left depicts the membrane structure and the active (black)
    or inactive (red) cell signals in glioma cells. High PE and low SM levels favor
    the activation of the MAPK pathway, which in turn induces the activity of the
    cyclin-CDK and PI3K pathways. The illustration on the right depicts the membrane
    lipid status in 2OHOA-treated cells, with more SM and less PE than untreated glioma
    cells, which causes the uncoupling of RAS and the concomitant inactivation of
    the MAPK and related pathways. Activation of FOXO1, overexpression of CDKN1B,
    hypophosphorylation of RB1 and inactivation of AKT1, contributes to the molecular
    scenario associated with the activation of autophagy in glioma but not normal
    cells. In this context, the membrane lipid structure appears to be the most upstream
    event that controls cell proliferation, differentiation and autophagy in glioma
    cells, SGMS thereby representing a new target for anticancer therapies.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK1
  - ELK1
  - PRKCZ
  - E2F1
  - CDKN1A
  - AKT1
  - PRKCQ
  - MAP2K5
  - CDKN1B
  - MAP2K4
  - NRAS
  - FOXO1
  - RAF1
  - CDK6
  - MAP2K7
  - MAP2K3
  - KRAS
  - AKT2
  - PRKCI
  - PRB1
  - MTOR
  - MAP2K1
  - AKT3
  - HRAS
  - PRKCB
  - PRKCE
  - MAP2K6
  - PRKCH
  - PRKCD
  - ARAF
  - PRKCA
  - MAP2K2
  - PRKD3
  - BRAF
  - PRKCG
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
genes:
- word: MAPK1/2
  symbol: MAPK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ELK1
  symbol: ELK1
  source: hgnc_symbol
  hgnc_symbol: ELK1
  entrez: '2002'
- word: MAPK1/2
  symbol: MAPK1
  source: hgnc_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCZ
  entrez: '5590'
- word: E2F1
  symbol: E2F1
  source: hgnc_symbol
  hgnc_symbol: E2F1
  entrez: '1869'
- word: CDKN1A
  symbol: CDKN1A
  source: hgnc_symbol
  hgnc_symbol: CDKN1A
  entrez: '1026'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCQ
  entrez: '5588'
- word: MAP2K
  symbol: MAP2K
  source: bioentities_symbol
  hgnc_symbol: MAP2K5
  entrez: '5607'
- word: CDKN1B
  symbol: CDKN1B
  source: hgnc_symbol
  hgnc_symbol: CDKN1B
  entrez: '1027'
- word: MAP2K
  symbol: MAP2K
  source: bioentities_symbol
  hgnc_symbol: MAP2K4
  entrez: '6416'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: FOXO1
  symbol: FOXO1
  source: hgnc_symbol
  hgnc_symbol: FOXO1
  entrez: '2308'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: CCND-CDK4/CDK6
  symbol: CDK6
  source: hgnc_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: MAP2K
  symbol: MAP2K
  source: bioentities_symbol
  hgnc_symbol: MAP2K7
  entrez: '5609'
- word: MAP2K
  symbol: MAP2K
  source: bioentities_symbol
  hgnc_symbol: MAP2K3
  entrez: '5606'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT1
  symbol: AKT1
  source: hgnc_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCI
  entrez: '5584'
- word: PRB1
  symbol: PRB1
  source: hgnc_symbol
  hgnc_symbol: PRB1
  entrez: '5542'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MAP2K
  symbol: MAP2K
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCE
  entrez: '5581'
- word: MAP2K
  symbol: MAP2K
  source: bioentities_symbol
  hgnc_symbol: MAP2K6
  entrez: '5608'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCH
  entrez: '5583'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCD
  entrez: '5580'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCA
  entrez: '5578'
- word: MAP2K
  symbol: MAP2K
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKD3
  entrez: '23683'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: PKC
  symbol: PKC
  source: bioentities_symbol
  hgnc_symbol: PRKCG
  entrez: '5582'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC3463457__F1
redirect_from: /figures/PMC3463457__F1
figtype: Figure
---
